3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Endocrine
1
CNS
1
Conditions
von Hippel-Lindau Disease
1
Pheochromocytoma
1
Paraganglioma
1
Adenoma, Islet Cell
1
Interventions
selpercatinib
2
lutetium Lu 177 dotatate
2
entrectinib
2
cabozantinib
2
Fulvestrant
2
trametinib
1
ribociclib
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
dabrafenib
1
copper dotatate CU-64
1
belzutifan
1
X-Rays
1
Specimen Handling
1
Phantoms, Imaging
1
Octreotide
1
Magnetic Resonance Spectroscopy
1
Lutetium-177
1
Lutetium
1
Alpelisib
1
3-Iodobenzylguanidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
belzutifan
×
Endocrine
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA